IOL Chemicals and Pharmaceuticals Limited

rs,

Complex, Bandra (E) Mumbai - 400 051 Security Symbol: IOLCP BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street Mumbai – 400 001 Security Code: 524164 Subject: Investor Presentation-Q1 FY2026.

120 MT

, is being carved out from the existing multiproduct Unit 9 and will have an installed capacity of 120 MTPA The project is expected to be completed by December 2025 at an estimated cost of ₹5.5 crore, ful

₹5.5 crore

acity of 120 MTPA The project is expected to be completed by December 2025 at an estimated cost of ₹5.5 crore, fully funded through internal accruals. land along the Chandigarh–Bathinda Highway, Acquired 1

15%

growth and capacity initiate expansion plans enhancement. to support Recognized among the top 15% of companies globally by EcoVadis for excellence in environmental, social, and ethical performance

₹ 551.7

mmitment to responsible and future-focused operations. 3 Q1 FY26 Performance Highlights Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit Aft

9.8%

ocused operations. 3 Q1 FY26 Performance Highlights Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% P

₹ 69.5

operations. 3 Q1 FY26 Performance Highlights Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceut

19.5%

1 FY26 Performance Highlights Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceuticals Chemicals

12.4%

ghlights Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceuticals Chemicals Geographical Break

₹ 34.0

s Q1 FY26 ₹ 551.7 Cr Revenue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceuticals Chemicals Geographical Break-up 295.

14.4%

nue from Operations 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceuticals Chemicals Geographical Break-up 295.7 322.3 329.3 206.7 2

6.1%

s 9.8% ₹ 69.5 Cr EBITDA 19.5% EBITDA Margin 12.4% ₹ 34.0 Cr Profit After Tax 14.4% PAT Margin 6.1% Pharmaceuticals Chemicals Geographical Break-up 295.7 322.3 329.3 206.7 205.5 222.4 24.4

“Initiated a dedicated project for the manufacture of Minoxidil and its intermediates.”

“A new facility, Unit 9B, is being carved out from the existing multiproduct Unit 9 and will have an installed capacity of 120 MTPA The project is expected to be completed by December 2025 at an estimated cost of ₹5.5 crore, fully funded through internal accruals.”

“Asia-Pacific—led by India and China posts the fastest growth at 8.7% CAGR.”

“Aiming to grow export revenue share to ~40% The company has acquired 101 acres of land alongside the Chandigarh- Bathinda Highway, near its existing facility, to support future expansion.”

Recognition

1

Existing Facility

1

COMPANY

1

INVESTOR RELATIONS ADVISORS

1

Recognition

EcoVadis Silver Medal • • • • • • • • Successfully obtained REACH registration under EU regulations for Acetic Anhydride The certification allows the company to export Acetic Anhyride across all the countries in the European Union. Initiated a dedicated project for the manufacture of Minoxidil and its intermediates. A new facility, Unit 9B, is being carved out from the existing multiproduct Unit 9 and will have an installed capacity of 120 MTPA The project is expected to be completed by December 2025 at an estimated cost of ₹5.5 crore, fully funded through internal accruals. land along the Chandigarh–Bathinda Highway, Acquired 101 acres of approximately 25 km from its existing facility The land is currently under regulatory approvals, post which the company will long-term growth and capacity initiate expansion plans enhancement. to support Recognized among the top 15% of companies globally by EcoVadis for excellence in environmental, social, and ethical performance The company has show

Existing Facility

Spanning 180+ acres Expansion: Acquired 101 acres on Chandigarh- Bathinda Highway for new site development Zero Discharge Effluent Treatment Plant Largest producer of Ibuprofen and the only company worldwide being backward integrated with ~30% Global share Customer base across 80 countries DSIR-approved R&D facility with 50+ scientists driving innovation across APIs and specialty chemicals Over 20 products are commercialized with 8 products in pipeline Major producer of Ethyl Acetate in India, producing 1,00,000 MTPA Debt to Equity Ratio 0.07 8 Segment Overview- Pharmaceuticals Largest global producer of Ibuprofen, with a ~30% market share and over 12,000 MT capacity World’s only company with full backward integration for all Ibuprofen intermediates and KSMs Filed 16 DMFs with USFDA and 19 CEPs with EDQM CEP certification received for 16 APIs, enabling exports to Europe and other CEP-accepting countries Commenced a fully backward-integrated Unit-11 for Paracetamol manufacturing at Barn

COMPANY

IOL Chemicals and Pharmaceuticals Ltd. CIN : L24116PB1986PLC007030 Mr. Abhay Raj Singh - Sr. VP & Company Secretary E-mail: investor@iolcp.com www.iolcp.com investor@iolcp.com www.iolcp.com Thank You

INVESTOR RELATIONS ADVISORS

MUFG Intime India Private Limited A part of MUFG Corporate Markets, a division of MUFG Pension & Market Services prachi.ambre@in.mpms.mufg.com Ms. Prachi Ambre prachi.ambre@in.mpms.mufg.com irfan.raeen@in.mpms.mufg.com Mr. Irfan Raeen irfan.raeen@in.mpms.mufg.com Meeting Request Link Link Website: https://in.mpms.mufg.com/